Neuroprotective Effect of Rapamycin (Autophagy Enhancer) in Transgenic SOD1-G93A Mice of Amyotrophic Lateral Sclerosis.
10.14253/kjcn.2013.15.2.53
- Author:
Suk Won AHN
1
;
Gye Sun JEON
;
Kwang Yeol PARK
;
Yoon Ho HONG
;
Kwang Woo LEE
;
Jung Joon SUNG
Author Information
1. Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Autophagy;
Rapamycin;
Amyotrophic lateral sclerosis;
ALS
- MeSH:
Amyotrophic Lateral Sclerosis*;
Animals;
Apoptosis;
Autophagy;
Cellular Structures;
Disease Progression;
Humans;
Mice*;
Mice, Transgenic;
Motor Neurons;
Neuroprotective Agents*;
Rotarod Performance Test;
Sirolimus*
- From:Korean Journal of Clinical Neurophysiology
2013;15(2):53-58
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The autophagy is the major route for lysosomal degradation of misfolded protein aggregates and oxidative cell components. We hypothesized that rapamycin (autophagy enhancer) would prolong the survival of motor neuron and suppress the disease progression in amyotrophic lateral sclerosis (ALS). METHODS: A total of 24 transgenic mice harboring the human G93A mutated SOD1 gene were used. The clinical status involving rotarod test and survival, and biochemical study of ALS mice model were evaluated. RESULTS: The onset of symptoms was significantly delayed in the rapamycin administration group compared with the control group. However, after the clinical symptom developed, the rapamycin exacerbated the disease progression and shortened the survival of ALS mice model, and apoptosis signals were up-regulated compared with control group. CONCLUSIONS: Even though further detailed studies on the relevancy between autophagy and ALS will be needed, our results revealed that the rapamycin administration was not effective for being novel promising therapeutic strategy in ALS transgenic mice and exacerbated the apoptosis.
